Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus tiragolumab vs atezolizumab plus placebo in first-line PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck
2023-509449-10-00Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Tecentriq + tiragolumab with Tecentriq + tiragolumab placebo (2 arms). Primary endpoint: Confirmed objective response rate. Started Jul 2024; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-509449-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509449-10-00.